{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T03:21:52Z","timestamp":1770607312878,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,7]]},"DOI":"10.7759\/cureus.103183","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:11:33Z","timestamp":1770531093000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness and Safety of Tapinarof 1% Cream in Psoriasis: An Observational Study From Bangladesh"],"prefix":"10.7759","author":[{"given":"Samiul","family":"Huq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Towhida","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abu","family":"Hena Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md.","family":"Abdul Latif Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anzirun","family":"Nahar Asma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snigdha","family":"Malabeka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur A","family":"Tasmin Tahnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahmidur","family":"Rahman Mahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shameem","family":"Al Mamun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afroza","family":"Jesmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: A systematic review of incidence and prevalence","volume":"133","author":"Parisi R","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013, 133:377-85. 10.1038\/jid.2012.339","journal-title":"J Invest Dermatol"},{"key":"ref2","article-title":"Prevalence of psoriasis in Bangladesh: A community based survey","volume":"30","author":"Bhuiyan MSI","year":"2020","unstructured":"Bhuiyan MSI, Sikder MS, Mahmud M, Nandy AK, Haque MM. Prevalence of psoriasis in Bangladesh: A community based survey. J Pak Assoc Dermatol. 2020, 30:39-45.","journal-title":"J Pak Assoc Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/22799036231181205","article-title":"Cross-cultural adaptation and validation of the Bangla version of the Psoriasis Disability Index","volume":"12","author":"Nishat F","year":"2023","unstructured":"Nishat F, Bhuiyan MS, Khan MA, Jesmin A, Khan MA, Hasan MJ. Cross-cultural adaptation and validation of the Bangla version of the Psoriasis Disability Index. J Public Health Res. 2023, 12:22799036231181205. 10.1177\/22799036231181205","journal-title":"J Public Health Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.30574\/wjarr.2021.10.2.0207","article-title":"Psycho-social determinants and magnitude of public health problems of psoriasis in Bangladesh","volume":"10","author":"Huq MS","year":"2021","unstructured":"Huq MS, Chowdhury AH, Noor T, Huq S. Psycho-social determinants and magnitude of public health problems of psoriasis in Bangladesh. World J Adv Res Rev. 2021, 10:108-18. 10.30574\/wjarr.2021.10.2.0207","journal-title":"World J Adv Res Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3329\/fmcj.v5i1.6807","article-title":"Pattern of skin diseases in patients attending OPD of dermatology department at Faridpur Medical College Hospital, Bangladesh","volume":"5","author":"Sarkar SK","year":"2011","unstructured":"Sarkar SK, Islam A, Sen KG, Ahmed ARS. Pattern of skin diseases in patients attending OPD of dermatology department at Faridpur Medical College Hospital, Bangladesh. Faridpur Med Coll J. 2011, 5:14-6. 10.3329\/fmcj.v5i1.6807","journal-title":"Faridpur Med Coll J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3329\/cemecj.v5i2.61490","article-title":"Prevalence, clinical pattern and presentations of psoriasis in a tertiary care hospital of Bangladesh","volume":"5","author":"Kalam MA","year":"2021","unstructured":"Kalam MA, Islam KA, Akber EB, Jahan I. Prevalence, clinical pattern and presentations of psoriasis in a tertiary care hospital of Bangladesh. Cent Med Coll J. 2021, 5:102-5. 10.3329\/cemecj.v5i2.61490","journal-title":"Cent Med Coll J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies","volume":"60","author":"Menter A","year":"2009","unstructured":"Menter A, Korman NJ, Elmets CA, et al.. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009, 60:643-59. 10.1016\/j.jaad.2008.12.032","journal-title":"J Am Acad Dermatol"},{"key":"ref8","unstructured":"American Academy of Dermatology Association. Psoriasis Clinical Guideline. (2025). Accessed. January 7, 2026: https:\/\/www.aad.org\/member\/clinical-quality\/guidelines\/psoriasis."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee HJ","year":"2023","unstructured":"Lee HJ, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. 2023, 24:13313. 10.3390\/ijms241713313","journal-title":"Int J Mol Sci"},{"key":"ref10","article-title":"Real-world use of tapinarof cream 1% once daily in patients with seborrheic dermatitis: A case series","volume":"18","author":"Issa NT","year":"2025","unstructured":"Issa NT, Pomaville L. Real-world use of tapinarof cream 1% once daily in patients with seborrheic dermatitis: A case series. J Clin Aesthet Dermatol. 2025, 18:24-8.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that\u00a0resolves skin inflammation in mice\u00a0and\u00a0humans","volume":"137","author":"Smith SH","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, et al.. Tapinarof is a natural AhR agonist that\u00a0resolves skin inflammation in mice\u00a0and\u00a0humans. J Invest Dermatol. 2017, 137:2110-9. 10.1016\/j.jid.2017.05.004","journal-title":"J Invest Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl MG","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Strober B, et al.. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021, 385:2219-29. 10.1056\/NEJMoa2103629","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.12-a.s1","article-title":"Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor","volume":"29","author":"Armstrong AW","year":"2023","unstructured":"Armstrong AW, McConaha JL. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor. J Manag Care Spec Pharm. 2023, 29:S1-S13. 10.18553\/jmcp.2023.29.12-a.s1","journal-title":"J Manag Care Spec Pharm"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING\u00a03 trial","volume":"87","author":"Strober B","year":"2022","unstructured":"Strober B, Stein Gold L, Bissonnette R, et al.. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING\u00a03 trial. J Am Acad Dermatol. 2022, 87:800-6. 10.1016\/j.jaad.2022.06.1171","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_420_23","article-title":"Disease assessment in psoriasis","volume":"68","author":"Manchanda Y","year":"2023","unstructured":"Manchanda Y, De A, Das S, Chakraborty D. Disease assessment in psoriasis. Indian J Dermatol. 2023, 68:278-81. 10.4103\/ijd.ijd_420_23","journal-title":"Indian J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S169333","article-title":"The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA","volume":"8","author":"Walsh JA","year":"2018","unstructured":"Walsh JA, Jones H, Mallbris L, Duffin KC, Krueger GG, Clegg DO, Szumski A. The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl). 2018, 8:65-74. 10.2147\/PTT.S169333","journal-title":"Psoriasis (Auckl)"},{"key":"ref17","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2017). Accessed. 12 January 2026: https:\/\/www.cancer.gov\/research\/resources\/resource\/210."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: Mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy S","year":"2016","unstructured":"Ramamoorthy S, Cidlowski JA. Corticosteroids: Mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016, 42:15-31, vii. 10.1016\/j.rdc.2015.08.002","journal-title":"Rheum Dis Clin North Am"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00235","article-title":"Regulatory and mechanistic actions of glucocorticoids on T and inflammatory cells","volume":"9","author":"Liberman AC","year":"2018","unstructured":"Liberman AC, Budzi\u00f1ski ML, Sokn C, Gobbini RP, Steininger A, Arzt E. Regulatory and mechanistic actions of glucocorticoids on T and inflammatory cells. Front Endocrinol (Lausanne). 2018, 9:235. 10.3389\/fendo.2018.00235","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051087","article-title":"Aryl hydrocarbon receptors: Evidence of therapeutic targets in chronic inflammatory skin diseases","volume":"10","author":"Kim HB","year":"2022","unstructured":"Kim HB, Um JY, Chung BY, Kim JC, Kang SY, Park CW, Kim HO. Aryl hydrocarbon receptors: Evidence of therapeutic targets in chronic inflammatory skin diseases. Biomedicines. 2022, 10:1087. 10.3390\/biomedicines10051087","journal-title":"Biomedicines"},{"key":"ref21","article-title":"Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: A randomized, double-blind, placebo-controlled multicenter trial","volume":"125","author":"Yang HZ","year":"2012","unstructured":"Yang HZ, Wang K, Jin HZ, et al.. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: A randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl). 2012, 125:1845-51.","journal-title":"Chin Med J (Engl)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0408-z","article-title":"Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and skin of color: Results from the pooled AMAGINE-2\/-3 randomized trials","volume":"20","author":"McMichael A","year":"2019","unstructured":"McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF. Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and skin of color: Results from the pooled AMAGINE-2\/-3 randomized trials. Am J Clin Dermatol. 2019, 20:267-76. 10.1007\/s40257-018-0408-z","journal-title":"Am J Clin Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01008-9","article-title":"Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Case photography of clinical outcomes from three phase\u00a03 trials","volume":"13","author":"Desai SR","year":"2023","unstructured":"Desai SR, Stein Gold L, Cameron MC, et al.. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Case photography of clinical outcomes from three phase\u00a03 trials. Dermatol Ther (Heidelb). 2023, 13:2443-60. 10.1007\/s13555-023-01008-9","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/457290-real-world-effectiveness-and-safety-of-tapinarof-1-cream-in-psoriasis-an-observational-study-from-bangladesh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:11:34Z","timestamp":1770531094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/457290-real-world-effectiveness-and-safety-of-tapinarof-1-cream-in-psoriasis-an-observational-study-from-bangladesh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.103183","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,7]]}}}